Year
2018
Status
Active
Team
Field
Target discovery
Location
Ghent (Belgium)
Fund
BGV III
Confo Therapeutics
Confo Therapeutics employs its proprietary CONFO® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery.